Amicus Therapeutics Share Price (NASDAQ: FOLD)

$7.58

▲

-0.07

(-0.92%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Amicus Therapeutics Stock chart to analyse performance

Amicus Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$7.57
Today's High:$7.73
$7.58
0.2%
Downside
Day's Volatility :2.13%
Upside
1.94%
52 Weeks Low:$5.51
52 Weeks High:$12.65
$7.58
27.31%
Downside
52 Weeks Volatility :56.44%
Upside
40.08%

Amicus Therapeutics Stock Returns

Period	Amicus Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	23.05%	3.6%	0.0%
6 Months	-16.98%	-7.7%	0.0%
1 Year	-34.82%	-12.6%	0.0%
3 Years	-34.43%	9.5%	-4.7%

Amicus Therapeutics, Inc. Key Stats

Check Amicus Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$7.65
Open	$7.65
Today's High	$7.73
Today's Low	$7.565
Market Capitalization	$2.3B
Today's Volume	$4.2M
52 Week High	$12.65
52 Week Low	$5.51
Revenue TTM	$571.2M
EBITDA	$32.9M
Earnings Per Share (EPS)	$-0.12
Profit Margin	-6.67%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-22.62%

Stock Returns calculator for Amicus Therapeutics Stock including INR - Dollar returns

The Amicus Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Amicus Therapeutics investment value today

Current value as on today

₹70,460

Returns

₹29,540

(-29.54%)

Returns from Amicus Therapeutics Stock

₹34,824 (-34.82%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Amicus Therapeutics Stock

41%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Amicus Therapeutics Stock from India on INDmoney has increased by 41% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Amicus Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
9.54%
Wellington Management Company LLP
9.45%
BlackRock Inc
9.03%
venBio Select Advisor LLC
5.84%
William Blair Investment Management, LLC
4.75%
State Street Corp
3.09%

Analyst Recommendation on Amicus Therapeutics Stock

Rating

Trend

Buy

76%Buy

23%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Amicus Therapeutics(by analysts ranked 0 to 5 stars)

Amicus Therapeutics Share Price Target

What analysts predicted

Upside of 112.28%

Target:

$16.09

Current:

$7.58

Amicus Therapeutics share price target is $16.09, a slight Upside of 112.28% compared to current price of $7.58 as per analysts' prediction.

Amicus Therapeutics Stock Insights

Price Movement
In the last 1 month, FOLD stock has moved up by 23.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 125.24M → 154.68M (in $), with an average increase of 19.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 14.73M → -24.42M (in $), with an average decrease of 129.9% per quarter
FOLD vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 104.6%
FOLD vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 145.5%
Price to Sales
ForFOLD every $1 of sales, investors are willing to pay $4.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Amicus Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$182.2M	↑ 99.72%
Net Income	$-356.4M	↑ 2.12%
Net Profit Margin	-195.56%	↑ 186.92%

	FY20	Y/Y Change
Revenue	$260.9M	↑ 43.16%
Net Income	$-276.9M	↓ 22.32%
Net Profit Margin	-106.12%	↑ 89.44%

	FY21	Y/Y Change
Revenue	$305.5M	↑ 17.11%
Net Income	$-250.5M	↓ 9.53%
Net Profit Margin	-81.98%	↑ 24.14%

	FY22	Y/Y Change
Revenue	$329.2M	↑ 7.76%
Net Income	$-236.6M	↓ 5.55%
Net Profit Margin	-71.85%	↑ 10.13%

	FY23	Y/Y Change
Revenue	$399.4M	↑ 21.3%
Net Income	$-151.6M	↓ 35.92%
Net Profit Margin	-37.96%	↑ 33.89%

	FY24	Y/Y Change
Revenue	$528.3M	↑ 32.29%
Net Income	$-56.1M	↓ 62.99%
Net Profit Margin	-10.62%	↑ 27.34%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$110.4M	↓ 4.07%
Net Income	$-48.4M	↑ 43.07%
Net Profit Margin	-43.86%	↓ 14.45%

	Q2 FY24	Q/Q Change
Revenue	$126.7M	↑ 14.73%
Net Income	$-15.7M	↓ 67.58%
Net Profit Margin	-12.39%	↑ 31.47%

	Q3 FY24	Q/Q Change
Revenue	$141.5M	↑ 11.72%
Net Income	$-6.7M	↓ 57.13%
Net Profit Margin	-4.75%	↑ 7.64%

	Q4 FY24	Q/Q Change
Revenue	$149.7M	↑ 5.79%
Net Income	$14.7M	↓ 319.04%
Net Profit Margin	9.85%	↑ 14.6%

	Q1 FY25	Q/Q Change
Revenue	$125.2M	↓ 16.34%
Net Income	$-21.7M	↓ 247.13%
Net Profit Margin	-17.31%	↓ 27.16%

	Q2 FY25	Q/Q Change
Revenue	$154.7M	↑ 23.5%
Net Income	$-24.4M	↑ 12.61%
Net Profit Margin	-15.79%	↑ 1.52%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$160.3M	↑ 108.58%

	FY20	Y/Y Change
Profit	$229.8M	↑ 43.41%

	FY21	Y/Y Change
Profit	$271.0M	↑ 17.93%

	FY22	Y/Y Change
Profit	$290.6M	↑ 7.23%

	FY23	Y/Y Change
Profit	$362.0M	↑ 24.57%

	FY24	Y/Y Change
Profit	$475.4M	↑ 31.3%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$94.7M	↓ 6.79%

	Q2 FY24	Q/Q Change
Profit	$113.2M	↑ 19.59%

	Q3 FY24	Q/Q Change
Profit	$128.2M	↑ 13.26%

	Q4 FY24	Q/Q Change
Profit	$134.9M	↑ 5.17%

	Q1 FY25	Q/Q Change
Profit	$113.6M	↓ 15.81%

	Q2 FY25	Q/Q Change
Profit	$139.5M	↑ 22.83%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-250.4M	↓ 16.52%
Investing Cash Flow	$95.2M	↓ 178.51%
Financing Cash Flow	$217.5M	↓ 51.75%

	FY20	Y/Y Change
Operating Cash Flow	$-233.3M	↓ 6.84%
Investing Cash Flow	$-13.6M	↓ 114.27%
Financing Cash Flow	$262.9M	↑ 20.85%

	FY21	Y/Y Change
Operating Cash Flow	$-202.5M	↓ 13.2%
Investing Cash Flow	$78.8M	↓ 680.02%
Financing Cash Flow	$212.1M	↓ 19.32%

	FY22	Y/Y Change
Operating Cash Flow	$-166.6M	↓ 17.74%
Investing Cash Flow	$92.3M	↑ 17.21%
Financing Cash Flow	$-7.5M	↓ 103.52%

	FY23	Y/Y Change
Operating Cash Flow	$-69.1M	↓ 58.52%
Investing Cash Flow	$98.1M	↑ 6.23%
Financing Cash Flow	$61.7M	↓ 926.44%

	FY24	Y/Y Change
Operating Cash Flow	$-33.9M	↓ 50.95%
Investing Cash Flow	$-560.0K	↓ 100.57%
Financing Cash Flow	$5.1M	↓ 91.7%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-29.7M	↓ 958.73%
Investing Cash Flow	$7.5M	↓ 131.46%
Financing Cash Flow	$-13.3M	↓ 262.11%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$22.7M	↓ 176.41%
Investing Cash Flow	$-22.0M	↓ 391.59%
Financing Cash Flow	$-857.0K	↓ 93.56%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-23.0M	↓ 201.23%
Investing Cash Flow	$34.3M	↓ 255.94%
Financing Cash Flow	$18.2M	↓ 2222.52%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-3.9M	↓ 82.95%
Investing Cash Flow	$-20.4M	↓ 159.5%
Financing Cash Flow	$1.1M	↓ 93.97%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$7.8M	↓ 298.11%
Investing Cash Flow	$-32.9M	↑ 61.15%
Financing Cash Flow	$-11.7M	↓ 1166.55%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-26.5M	↓ 441.92%
Investing Cash Flow	$-5.8M	↓ 82.42%
Financing Cash Flow	$-400.0K	↓ 96.58%

Amicus Therapeutics Technicals Summary

Sell

Neutral

Buy

Amicus Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Amicus Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amicus Therapeutics, Inc.	26.54%	-16.98%	-34.82%	-34.43%	-46.16%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amicus Therapeutics, Inc.	NA	NA	-0.18	0.32	-0.23	0.02	NA	0.66
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amicus Therapeutics, Inc.	Buy	$2.3B	-46.16%	NA	-6.67%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

Amicus Therapeutics Dividend announcements

Amicus Therapeutics Earnings
Amicus Therapeutics’s price-to-earnings ratio stands at None

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Organization	Amicus Therapeutics
Employees	499
CEO	Mr. Bradley L. Campbell M.B.A.
Industry	Health Technology

Key Management of Amicus Therapeutics, Inc.

Name	Title
Mr. Bradley L. Campbell M.B.A.	CEO, President & Director
Mr. Simon Nicolas Reade Harford	Chief Financial Officer
Ms. Ellen S. Rosenberg J.D.	Chief Legal Officer & Corporate Secretary
Mr. David M. Clark	Chief People Officer
Dr. Jeffrey P. Castelli Ph.D.	Chief Development Officer
Ms. Samantha L. Prout	Chief Accounting Officer & Controller
Dr. Jill Weimer Ph.D.	Chief Science Officer
Mr. Andrew Faughnan	Vice President of Investor Relations
Mr. Patrik S. Florencio Esq.	Global Chief Compliance & Risk Officer
Ms. Diana Moore	Head of Global Corporate Communications

Important FAQs about investing in FOLD Stock from India :

What is Amicus Therapeutics share price today?

Amicus Therapeutics share price today is $7.58 as on August 30, 2025 at 1:29 am IST at the close of the market. Amicus Therapeutics share today touched a day high of $7.73 and a low of $7.57.

What is the 52 week high and 52 week low for Amicus Therapeutics share?

Amicus Therapeutics share touched a 52 week high of $12.65 and a 52 week low of $5.51. Amicus Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $7.58, lower by 40.08% versus the 52 week high.

How to invest in Amicus Therapeutics Stock (FOLD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Amicus Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amicus Therapeutics Shares that will get you 0.1979 shares as per Amicus Therapeutics share price of $7.58 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Amicus Therapeutics Stock (FOLD) from India?

Indian investors can start investing in Amicus Therapeutics (FOLD) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Amicus Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Amicus Therapeutics share’s latest price of $7.58 as on August 30, 2025 at 1:29 am IST, you will get 1.3193 shares of Amicus Therapeutics. Learn more about fractional shares .

What are the returns that Amicus Therapeutics has given to Indian investors in the last 5 years?

Amicus Therapeutics stock has given -46.16% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?